Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma

NCT ID: NCT04887025

Last Updated: 2023-02-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-02-08
• Study Completion Date: 2025-03-15

Brief Summary

This is a dose-escalation, single-arm, single-center open study which aims to evaluate the maximum tolerated dose (MTD) and dose-dependent toxicity (DLT) of a novel oncolytic vaccinia virus expressing bispecific antibody RGV004 in patients with relapsed/refractory B-cell lymphoma,

Detailed Description

Oncolytic vaccinia virus administered by intratumoral injection

Conditions

Relapsed or Refractory B-cell Lymphoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dose Escalation

Subjects will be treated with RGV004 as a single injection, one time.

Group Type: EXPERIMENTAL

RGV004

Intervention Type: BIOLOGICAL

a genetically-engineered vaccinia virus (encoding CD19/CD3 bispecific antibody)

Interventions

RGV004

a genetically-engineered vaccinia virus (encoding CD19/CD3 bispecific antibody)

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 18 years old, the upper limit is 75 years old, there is no restriction on men and women;

2. ECOG score 0-1;

3. Histological diagnosis of non-Hodgkin B-cell lymphoma (NHL) [diagnostic criteria according to WHO2008], including diffuse large B-cell lymphoma (DLBCL) non-specific, primary mediastinal large B-cell lymphoma (PMBCL) , Mantle cell lymphoma (MCL), transformed follicles Cell lymphoma (TFL) and other indolent B-cell NHL transformants;

4. CD19 positive (immunohistochemistry or flow cytometry);

5. DLBCL refractory (refractory) or relapse is defined as: complete remission is not achieved after 2-line treatment; disease appears during any treatment Disease progression, or disease stable time equal to or less than 6 months; or disease progression or recurrence within 12 months after autologous hematopoietic stem cell transplantation;

6. MCL: Complete remission has not been achieved after 2-line treatment (including BTK inhibitors); disease progression during any treatment, or disease stable time equal to or less than 6 months; or within 12 months after autologous hematopoietic stem cell transplantation Disease progression or recurrence;

7. There is at least one measurable superficial lesion, and any long diameter of the lymph node lesion is greater than 1.5 cm or any long diameter of the extranodal lesion is greater than 1.0 cm, and the PET-CT scan lesion is ingested (SUV is greater than the liver blood pool);

8. Peripheral blood neutrophil absolute value ≥ 2000/mm3, platelet ≥ 50,000/mm3;

9. Heart, liver and kidney functions: creatinine <1.5mg/dL; ALT (alanine aminotransferase) / AST (aspartate aminotransferase) below 2.5 times the upper limit of normal; total bilirubin <1.5mg/dL; cardiac ejection fraction ( EF) ≥50%;

10. Have sufficient understanding and voluntarily sign the informed consent form;

11. Women with fertility must undergo a negative serum pregnancy test and agree to implement effective birth control measures during the treatment phase and within 60 days after the last application of the oncolytic virus;

12. Male patients must agree to implement effective birth control measures during the study period and within 60 days after the last viral treatment.

Exclusion Criteria

1. There is a history of other tumors;

2. Inoculate vaccinia vaccine 3 months before the study treatment and during the study treatment period;

3. Have received gene therapy or any type of oncolytic virus therapy within 3 months before the study treatment;

4. Other open wounds;

5. Active autoimmune diseases;

6. Active infection that cannot be controlled;

7. HIV infection, uncontrolled HBV, HCV, and syphilis infection;

8. Known lymphoma of the central nervous system;

9. Clinically important heart disease;

10. Allergic to albumin or egg products;

11. Have undergone similar operations such as organ transplantation;

12. Systemic treatment of skin diseases is required;

13. A history of severe systemic reactions or side effects after vaccinia vaccine injection;

14. Known dependence on alcohol or viruses;

15. Pregnant or lactating female patients

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hangzhou Rongu Biotechnology Co., Ltd.

UNKNOWN

Sponsor Role: collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Wenbin Qian

Role: PRINCIPAL_INVESTIGATOR

2nd Affiliated Hospital, School of Medicine, Zhejiang University

Locations

2nd Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

Site Status: RECRUITING

Countries

China

Central Contacts

Wenbin Qian

Role: CONTACT

qianwb@zju.edu.cn

+8613605801032

Facility Contacts

Wenbin Qian, M.D.,PhD.

Role: primary

qianwb@zju.edu.cn

+8613605801032

Other Identifiers

IR2021002042

Identifier Type: -

Identifier Source: org_study_id